Acumen Pharmaceuticals conducted a Phase 2 clinical trial in Canada, with results presented in Toronto and Newton, Massachusetts on July 28, 2025.
2 reports, 1 independent
Updated Jul 28
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Acumen Pharmaceuticals conducted a Phase 2 clinical trial in Canada, with results presented in Toronto and Newton, Massachusetts on July 28, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Acumen Pharmaceuticals presented Phase 2 trial results in Toronto and Newton, MA.1 source
Upcoming presentation of Acumen findings in Toronto.1 source
Keep exploring
The entities involved
-
Acumen Pharmaceuticals (United States)
company in Livermore, United States
Nothing else this week.
-
Toronto
capital and largest city of the province of Ontario, Canada
-
Newton
city in Massachusetts, United States
Related events
Coverage
Newest first; wire copies grouped- GlobeNewswireAcumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s As
- GlobeNewswireAcumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association